Navigation Links
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
Date:6/18/2008

0:

1) Predicting response to treatment of ovarian cancer patients

- Platinum-based cytotoxic chemotherapy in conjunction with debulking surgery is currently the gold standard of treatment for patients with ovarian cancer. However, approximately 20-50% of patients do not respond to platinum-based chemotherapy and will require additional second line treatment. Furthermore, research suggests that administering platinum-based treatment to patients who subsequently do not respond to it may actually hinder their response to the second line treatment as well. Rosetta Genomics has identified unique microRNA biomarkers that may assist in identifying ovarian cancer patients expected to benefit from platinum-based chemotherapy.

2) Predicting risk of gastric cancer recurrence - Recurrence after curative resection for gastric cancer is high and is estimated to occur in 50-80% of patients. This test will use microRNA molecular classification of gastric cancer samples to predict the risk of recurrence for non-metastatic patients after resection of the primary tumor.

3) Differentiating small from non-small cell lung cancer - An estimated 220,000(1) patients are diagnosed with lung cancer each year in the U.S. alone. Before a patient begins lung cancer treatment, an experienced lung cancer pathologist must review the pathologic material. This is critical because small cell lung cancer, which is generally not treated surgically, can be confused on microscopic examination with non-small cell carcinoma(2). Rosetta Genomics has identified unique microRNA biomarkers that may be used to differentiate small from non-small cell lung cancers.

In addition, utilizing its proprietary extraction and quantification microRNA technologies, the Company has recently identified microRNA biomarkers in the serum of colon cancer patients which may serve as the basis for a future blood-based test for colon cancer.

"Molecular diagnostic companies like Rosetta Genom
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... -   JOLT , a leading technology accelerator, announced ... growing portfolio of startups. Next-level tech and boundary-pushing innovation ... JOLT accelerator, and Cohort four is no exception, with ... Since its launch in July 2012, JOLT has produced ... Now at 23 investments, JOLT,s portfolio has an overall ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health ... disease, announced the hire of Brad Towle ... will be responsible for driving the company,s sales growth, ... experience in healthcare, and specifically his past role in ... to the company at this pivotal time in the ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... , , ... 8 /PRNewswire-Asia/ -- The Jiangsu Government,s,Science and Technology Department ... Achievements Transformational Grant - to support the,research and development ... grant recipient and administrator, Shenzhen Beike,Biotechnology Co., Ltd. ( ...
... , NORTH BILLERICA, Mass., Dec. 29 ... of instruments for measuring cellular bioenergetics, announced that TheScientist ... 2009 Top Ten Innovation. , A panel of scientific experts ... the first instrument to measure the two energy pathways of ...
... , ORLANDO, Fla., Dec. 28 ... a leading consumer genomics and biotechnology company ( www.genelinkbio.com ), ... as its interim Chief Executive Officer, effective December 28, 2009. ... with more than 25 years of experience building high performance ...
Cached Biology Technology:Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 2Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 3Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 4TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009 2David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 2David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 3David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 4
(Date:7/28/2014)... Wyss Institute for Biologically Inspired Engineering at Harvard ... will be commercialized by a newly formed private ... and personalized medicine products. The announcement ... of Technology Development (OTD) and the start-up Emulate ... automated human Organs-on-Chips platform. , "This is ...
(Date:7/27/2014)... wiped them out if it had taken place slightly ... fresh study using up-to-date fossil records and improved analytical ... of the prehistoric creatures, demise, some 66 million years ... years before a 10km-wide asteroid struck what is now ... volcanic activity, changing sea levels and varying temperatures. ...
(Date:7/27/2014)... studies have shown the potential for global climate change ... the most part, ignored the interactions between increasing temperature ... known to damage crops. , A new study involving ... quite significant, suggesting that policymakers need to take both ... security. , The study looked in detail at global ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... the most rapidly increasing food production system worldwide through ... 2009 issue of BioScience . The assessment, by ... Ann Arbor, notes that despite well-publicized concerns about ... practiced well, be no more damaging to biodiversity than ...
... has worked out how some newly discovered light sensors ... brain. The report appears online this week in ... small number of nerve cells in the retina that ... retinarods and conesmelanopsin-containing cells are not used for seeing ...
... DNA modification in lung cancer, a team of international researchers ... They say that "silencing" of a single gene in lung ... cells, contributing to cancer development and progression. In the ... journal of the American Association for Cancer Research, they also ...
Cached Biology News:Aquaculture's growth seen as continuing 2Bright lights, not-so-big pupils 2Bright lights, not-so-big pupils 3In lung cancer, silencing one crucial gene disrupts normal functioning of genome 2In lung cancer, silencing one crucial gene disrupts normal functioning of genome 3
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Request Info...
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
Biology Products: